Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CSBR, unsubscribe in one click. Privacy
CSBR holds $4.4M in cash and short-term investments (as of Jul 31, 2026) and burns about $1.2M/quarter from operations, an estimated runway of 10.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 30 · Moderate
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CSBR files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CSBR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →